Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELIXA: Lixisenatide CV Outcomes in T2DM Post-ACS
NCT01147250Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jun 2010
- Primary completion
- Feb 2015
- Modality
- Peptides
- Countries
- 49
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Lixisenatide with Placebo (2 arms). Primary endpoint: Time to First Occurrence of Primary CV Event (CV Death, Non-Fatal MI, Non-Fatal Stroke or Hospitalization for Unstable Angina) at 25 months. Started Jun 2010; status: completed.
02
Drugs
lixisenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01147250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01147250.